Adults with stage IB – IV melanoma are invited to be in a research study testing a melanoma vaccine (Mel 66)

UVA Tracking #
HSR200006
Principal Investigator
Craig L Slingluff
Contact
Adela Mahmutovic
Contact Phone
434.982.6914
Official Trial Title
ENHANCED MELANOMA VACCINE AGAINST NEOANTIGEN AND SHARED ANTIGENS BY CD40 ACTIVATION AND TLR AGONISTS IN PATIENTS WITH STAGE II-IV MELANOMA (UVA MEL 66)
Study Description

The UVA Cancer Center seeks adults with primary cutaneous, mucosal, or unknown melanoma (stage IB ulcerated, II, III, or IV melanoma) or stage II, III, or IV uveal melanoma for a research study. The purpose of the study is to test the effectiveness of a melanoma vaccine made of peptides (short pieces of proteins found in melanoma and sometimes normal cells) called 6MHP and NeoAg-mBRAF, as well as adjuvants (which help your body make immune responses against the proteins) called CDX-1140 and polyICLC.

You may be eligible for this study if you have been determined to be free of disease in the last 6 months.

The study involves getting a vaccine in one place in your body four times. The vaccines are usually given in an arm or a leg. The study also involves having a biopsy where the vaccine is given. Blood will be drawn 8 times for study purposes. If you have at least 4 moles, you can also have your moles studied and biopsied as part of this clinical trial, but this is optional. During the active treatment portion of the study, you will come in for up to 7 visits over 176 days (about 6 months). Each visit will last about 2 to 7 hours.

Study-related procedures, including but not limited to the biopsy and vaccine, will be provided at no cost.

For more information, please visit https://clinicaltrials.gov/ct2/show/NCT04364230

Compensation

No Compensation